Table 1 Pharmacologic profile of top candidate antivirals

From: Limitations of acyclovir and identification of potent HSV antivirals using 3D bioprinted human skin equivalents

Candidate antiviral

Primary mechanism of action

Target

Submerged

ALI

Curve Class

Max Inhibition (%)

IC50 (μM)

CC50 (μM)

Curve Class

Max Inhibition (%)

IC50 (μM)

CC50 (μM)

Amenamevir (AMN)

Helicase primase inhibitor

Viral

−1.1

85.31

0.27

>10

−1.1

112.36

0.16

>10

Pritelivir (PRT)

Helicase primase inhibitor

Viral

−1.1

94.64

0.50

>10

−1.2

101.90

0.21

>10

Fimepinostat (FMP)

PI3K/HDAC inhibitor

Host

−1.1

87.43

1.48

>10

−5

88.60

<0.04

>10

Fluoroemetine (FLR)

Unknown

Host

−1.1

96.50

0.15

>10

−1.1

111.83

0.22

>10

Gemcitabine (GMC)

Ribonucleotide Reductase

Host

−1.1

99.84

0.19

>10

−1.2

101.78

0.16

>10

Lanatoside C (LNT)

Autophagy inducer

Host

−1.1

106.86

0.09

2.49

−1.2

99.49

0.08

>10

LDC4297 (LDC)

CDK inhibitor

Host

−2.1

94.82

0.68

>10

−1.1

99.87

0.11

>10

Niclosamide (NCD)

Multi-functional

Host

−1.1

97.13

0.39

>10

−1.1

98.67

0.11

>10

SNX-2112 (SNX)

HSP90 inhibitor

Host

−1.2

101.78

0.05

1.14

−5

107.14

<0.04

>10

Verdinexor (VRD)

Exportin Antagonist

Host

−1.3

68.57

0.48

> 10

−1.1

107.81

0.17

>10

VLX1570 (VLX)

Protease deubiquitinase inhibitor

Host

−2.5

55.49

6.67

8.41

−1.1

101.22

0.16

>10

  1. Top candidate antivirals were selected from 41 compounds identified as potent and effective at doses below their respective CC50 in the primary and secondary screens. We re-tested these top candidate antivirals in triplicate and reported the Curve Class, Max Inhibition, IC50, and CC50.
Back to article page